These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Clinical assays for assessment of homologous recombination DNA repair deficiency. Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552 [TBL] [Abstract][Full Text] [Related]
4. Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective. Herzog TJ; Vergote I; Gomella LG; Milenkova T; French T; Tonikian R; Poehlein C; Hussain M Eur J Cancer; 2023 Jan; 179():136-146. PubMed ID: 36563604 [TBL] [Abstract][Full Text] [Related]
5. Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy. Gou R; Dong H; Lin B Life Sci; 2020 Nov; 261():118434. PubMed ID: 32941897 [TBL] [Abstract][Full Text] [Related]
6. Poly (adenosine diphosphate-ribose) polymerase inhibitors in the treatment of triple-negative breast cancer with homologous repair deficiency. Yuan P; Ma N; Xu B Med Res Rev; 2024 Nov; 44(6):2774-2792. PubMed ID: 38922930 [TBL] [Abstract][Full Text] [Related]
7. [Homologous recombination repair deficiency as a predictive biomarker : Basic mechanisms and detection methods]. Pfarr N; Merkelbach-Bruse S Pathologe; 2021 Jul; 42(4):391-398. PubMed ID: 34152463 [TBL] [Abstract][Full Text] [Related]
8. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Miller RE; Leary A; Scott CL; Serra V; Lord CJ; Bowtell D; Chang DK; Garsed DW; Jonkers J; Ledermann JA; Nik-Zainal S; Ray-Coquard I; Shah SP; Matias-Guiu X; Swisher EM; Yates LR Ann Oncol; 2020 Dec; 31(12):1606-1622. PubMed ID: 33004253 [TBL] [Abstract][Full Text] [Related]
9. Biomarkers for Homologous Recombination Deficiency in Cancer. Hoppe MM; Sundar R; Tan DSP; Jeyasekharan AD J Natl Cancer Inst; 2018 Jul; 110(7):704-713. PubMed ID: 29788099 [TBL] [Abstract][Full Text] [Related]
10. Recent Advances in Genomic Approaches for the Detection of Homologous Recombination Deficiency. Kim YN; Gulhan DC; Jin H; Glodzik D; Park PJ Cancer Res Treat; 2024 Oct; 56(4):975-990. PubMed ID: 39026430 [TBL] [Abstract][Full Text] [Related]
11. Prediction of homologous recombination deficiency from cancer gene expression data. Kang J; Lee J; Lee A; Lee YS J Int Med Res; 2022 Nov; 50(11):3000605221133655. PubMed ID: 36380518 [TBL] [Abstract][Full Text] [Related]
12. Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests. Meijer TG; Nguyen L; Van Hoeck A; Sieuwerts AM; Verkaik NS; Ladan MM; Ruigrok-Ritstier K; van Deurzen CHM; van de Werken HJG; Lips EH; Linn SC; Memari Y; Davies H; Nik-Zainal S; Kanaar R; Martens JWM; Cuppen E; Jager A; van Gent DC Oncogene; 2022 Jun; 41(26):3498-3506. PubMed ID: 35662281 [TBL] [Abstract][Full Text] [Related]
13. Homologous Recombination Deficiency: Concepts, Definitions, and Assays. Stewart MD; Merino Vega D; Arend RC; Baden JF; Barbash O; Beaubier N; Collins G; French T; Ghahramani N; Hinson P; Jelinic P; Marton MJ; McGregor K; Parsons J; Ramamurthy L; Sausen M; Sokol ES; Stenzinger A; Stires H; Timms KM; Turco D; Wang I; Williams JA; Wong-Ho E; Allen J Oncologist; 2022 Mar; 27(3):167-174. PubMed ID: 35274707 [TBL] [Abstract][Full Text] [Related]
14. Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types. Takamatsu S; Brown JB; Yamaguchi K; Hamanishi J; Yamanoi K; Takaya H; Kaneyasu T; Mori S; Mandai M; Matsumura N JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34423229 [TBL] [Abstract][Full Text] [Related]
15. Diagnosis of Ovarian Carcinoma Homologous Recombination DNA Repair Deficiency From Targeted Gene Capture Oncology Assays. Krumm N; Khasnavis NS; Radke M; Banda K; Davies HR; Pennil C; McLean K; Paulson VA; Konnick EQ; Johnson WC; Huff G; Nik-Zainal S; Swisher EM; Lockwood CM; Salipante SJ JCO Precis Oncol; 2023 May; 7():e2200720. PubMed ID: 37196218 [TBL] [Abstract][Full Text] [Related]
16. Homologous Recombination Deficiency (HRD) in Cutaneous Oncology. Akinjiyan FA; Morecroft R; Phillipps J; Adeyelu T; Elliott A; Park SJ; Butt OH; Zhou AY; Ansstas G Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445949 [TBL] [Abstract][Full Text] [Related]
17. Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors. Diossy M; Reiniger L; Sztupinszki Z; Krzystanek M; Timms KM; Neff C; Solimeno C; Pruss D; Eklund AC; Tóth E; Kiss O; Rusz O; Cserni G; Zombori T; Székely B; Kulka J; Tímár J; Csabai I; Szallasi Z Ann Oncol; 2018 Sep; 29(9):1948-1954. PubMed ID: 29917049 [TBL] [Abstract][Full Text] [Related]
18. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it? Ngoi NYL; Tan DSP ESMO Open; 2021 Jun; 6(3):100144. PubMed ID: 34015643 [TBL] [Abstract][Full Text] [Related]
19. RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox? van Wijk LM; Nilas AB; Vrieling H; Vreeswijk MPG Expert Rev Mol Diagn; 2022 Feb; 22(2):185-199. PubMed ID: 34913794 [TBL] [Abstract][Full Text] [Related]
20. Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency? Gourley C; Miller RE; Hollis RL; Ledermann JA Curr Opin Oncol; 2020 Sep; 32(5):442-450. PubMed ID: 32796232 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]